Altre lingue Nxera Pharma Co., Ltd. OTC Markets

Azioni

SOLTF

JP3431300007

Mercato chiuso - OTC Markets Altri mercati azionari 20:53:24 16/07/2024			Variaz. 5gg	Var. 1 gen.
10,23 ^USD	-0,09%		-0,09%	+2,30%

27/06	Nxera Pharma Co raggiunge una pietra miliare chiave di R&S nella collaborazione con AbbVie; ottiene un pagamento di 10 milioni di dollari	MT
27/06	Nxera Pharma Co., Ltd. riceve 10 milioni di dollari da AbbVie. riceve 10 milioni di dollari da AbbVie, mentre la collaborazione per le malattie neurologiche raggiunge il primo traguardo di ricerca e sviluppo.	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results	09/07
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	27/06
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27/06
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27/06
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023	18/06
Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	31/05
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05
Nxera Pharma Co., Ltd. and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	10/05
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	09/05
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024	09/05
Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18/04
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	17/04
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17/04
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16/04
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	15/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nxera Pharma Co., Ltd. OTC Markets

Azioni

SOLTF

JP3431300007

Altre lingue

Filtri